Update (June 25, 2026): Ciclosporin for Canine Atopic Dermatitis — Randomized Trial Evidence vs Methylprednisolone and Prednisolone

Bottom line.

• In a multicentre, parallel, blinded, randomized controlled trial comparing ciclosporin (CsA, 117 dogs) with methylprednisolone (MP, 59 dogs) over 4 months, the mean estimated percentage reduction from baseline in lesion scores was 52% (95% CI 44–59%) for the CsA group and 45% (35–56%) for the MP group; a significantly better overall assessment of efficacy was obtained in CsA-treated dogs (76% vs 63% responses rated excellent or good; P < 0.05).¹
• In a separate blinded randomized prednisolone-controlled trial of 30 dogs with nonseasonal atopic dermatitis, ciclosporin at 5 mg/kg once daily reduced skin lesion scores (CADESI) significantly from baseline at weeks 3 and 6 (P < 0.05); both drugs produced comparable improvement by week 6 but response was slower in the ciclosporin group during the first 3 weeks.²
• Ciclosporin-treated dogs had a higher frequency of gastrointestinal adverse events (mainly vomiting) compared with methylprednisolone; methylprednisolone-treated dogs tended to be more susceptible to infections.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Calcineurin inhibitor; immunomodulatory agent.¹
• Mechanism: Inhibits calcineurin, suppressing T-lymphocyte activation and downstream cytokine production (including IL-2, IL-4, IL-5, IFN-γ); modulates the inflammatory cascade central to atopic dermatitis pathogenesis.¹
• Route/interval: Oral, once daily in the key randomized trials (defer specific dose to current labeling and formulary).¹
• Indication discussed here: Efficacy and safety of ciclosporin for chronic canine atopic dermatitis.¹
• Key trial populations: Multicentre CsA vs MP trial: 176 dogs total at multiple sites; 4-month treatment period. Prednisolone-controlled trial: 30 dogs with nonseasonal AD; 6-week treatment period.^1,2

Managing a dog with chronic atopic dermatitis requiring immunomodulation?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Multicentre ciclosporin vs methylprednisolone RCT (Steffan et al. 2003)

The largest of the pivotal ciclosporin trials was a multicentre, parallel, blinded, randomized controlled study comparing ciclosporin (CsA group, 117 dogs) with methylprednisolone (MP group, 59 dogs) for 4 months.¹ The mean induction doses were approximately 5 mg/kg for cyclosporine A and 0.75 mg/kg for methylprednisolone, tapered over time according to clinical response. At the end of the study, the mean estimated percentage reduction from baseline (confidence interval) of lesion scores was 52% (44–59%) and 45% (35–56%), and the reduction in pruritus score was 36% (27–43%) and 33% (23–43%) in the CsA and MP groups respectively.¹ A significantly better overall assessment of efficacy was obtained in the CsA-treated dogs, with 76% rated excellent or good versus 63% in the MP group. CsA-treated dogs presented a higher frequency of gastrointestinal disorders, mainly vomiting; MP dogs tended to be more susceptible to infections.¹

Blinded prednisolone-controlled trial (Olivry et al. 2002)

In an earlier blinded, randomized, prednisolone-controlled study, 30 dogs with nonseasonal atopic dermatitis were allocated to receive oral ciclosporin (NEORAL, 5 mg/kg) or prednisolone (0.5 mg/kg) once daily for 6 weeks.² Skin lesion severity was assessed using CADESI before treatment and at 3 and 6 weeks. Ciclosporin significantly reduced skin lesions and pruritus from baseline at weeks 3 and 6; by week 6, the magnitude of improvement was broadly comparable between groups, though ciclosporin was slower to act during the initial phase of therapy.²

Onset of action and clinical implications

A consistent observation across trials is that ciclosporin has a slower onset of action than systemic glucocorticoids and oclacitinib. In a subsequent head-to-head blinded RCT comparing oclacitinib with ciclosporin in 226 dogs, pruritus VAS reductions from baseline were 25.6% for oclacitinib versus 6.5% for ciclosporin at day 1, with differences significant at all time points up to day 28.³ By day 84, the two agents converged in efficacy. This has led to the clinical practice of co-initiating a short course of glucocorticoid or oclacitinib to "bridge" the 4–6 week lag to full ciclosporin effect.

How this fits clinical practice

Ciclosporin remains a well-established, evidence-supported first-line option for chronic canine atopic dermatitis, particularly for long-term management where daily oral dosing is feasible. The 2015 ICADA guidelines identify oral ciclosporin as one of the medications most effective in reducing chronic pruritus and skin lesions in canine AD.⁴ Key monitoring parameters include renal function, blood pressure, and assessment for secondary infections (ciclosporin is immunosuppressive). Gastrointestinal adverse events, particularly vomiting, are the most commonly reported side effect and usually respond to dose reduction, temporary dose frequency reduction or administration with food. Ciclosporin has significant drug interactions and is metabolized by CYP3A4; interaction screening is essential before co-prescribing. Do not infer specific doses from this summary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Steffan J, Alexander D, Brovedani F, Fisch RD. 2003. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 14(1):11-22. https://pubmed.ncbi.nlm.nih.gov/12603681/
2. Olivry T, Rivierre C, Jackson HA, Murphy KM, Davidson G, Sousa CA. 2002. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 13(2):77-87. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-3164.2002.00283.x
3. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. 2015. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 26(1):23-30. https://onlinelibrary.wiley.com/doi/abs/10.1111/vde.12186
4. Olivry T, DeBoer DJ, Favrot C, et al.; International Committee on Allergic Diseases of Animals. 2015. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11:210. https://pubmed.ncbi.nlm.nih.gov/26276051/

Changelog

• 2026-06-25: First published.